Treatment of Hemoglobinopathies: From Blood to Bone Marrow and Beyond
Track
:
TC - Technical/Clinical
Program Code:
9220-TC-CT
Date:
Sunday, October 13, 2013
Time:
4:00 PM to 5:30 PM
EST
Location:
601/603
DIRECTOR
:
Dr. Naynesh Kamani, MD
MODERATOR
:
Dr. Naynesh Kamani, MD
SPEAKER
(S):
Dr. Farid Boulad, MD, Medical Director, Pediatric Day Hospital, Memorial Sloan-Kettering Cancer Center
Dr. Naynesh Kamani, MD
Dr. Shalini Shenoy, MD, Director, Pediatric Stem Cell Transplant Program, Washington University/St. Louis Children's Hospital
Description
The two most prevalent hemoglobinopathies are thalassemia major and sickle cell disease. Regular blood transfusions are the mainstay of therapy for those with thalassemia major and severe symptomatic sickle cell disease. Hematopoietic stem cell transplantation is the only known curative therapy currently available but clinical trials for gene therapy trials for these disorders are now underway. This session will compare currently available therapies and provide attendees with state of the art updates on current clinical trials of HSCT and gene therapy for the hemoglobinopathies.
Compare and contrast chronic blood transfusions with hematopoietic stem cell transplantation (HSCT) for the hemoglobinopathies.
Discuss current gene therapy trials for the hemoglobinopathies.
Provide an update on outcomes following HSCT for the hemoglobinopathies with current clinical trials for eligible patients without matched sibling donors.
CE Category
CE Value
California Clinical Laboratory Personnel
1.5
California Nurse
1.8
Florida Laboratory Personnel
1.8
General Attendee
1.5
Physician
1.5
Please note: Continuing education (CE) credit is available for online offerings only. Individuals that purchase CD-ROMs will not receive CE credit for the programs they view.